Pharmacist Medication Insights: Octagam for Chronic Immune Thrombocytopenic Purpura

Video

Octagam 10% is indicated for the treatment of chronic immune thrombocytopenic purpura in adults and dermatomyositis (DM) in adults

Octagam 10% is an immune globulin intravenous (human) liquid preparation indicated for the treatment of:

  • Chronic immune thrombocytopenic purpura (ITP) in adults
  • Dermatomyositis (DM) in adults

Further, Octagam 10% is the first and only intravenous immunoglobulin to be indicated for the treatment of adult dermatomyositis.

Recent Videos
Naloxone concept represented by wooden letter tiles.
Hand holding a Narcan Evzio Naloxone nasal spray opioid drug overdose prevention medication
Catalyst Trial, Diabetes, Hypertension | Image Credit: grinny - stock.adobe.com
male pharmacist using digital tablet during inventory in pharmacy | Image Credit: sofiko14 - stock.adobe.com
Pharmacist holding medicine box in pharmacy drugstore. | Image Credit: I Viewfinder - stock.adobe.com
Pharmacy Drugstore Checkout Cashier Counter | Image Credit: Gorodenkoff - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
Related Content
FDA Approval | Image Credit: outchill - stock.adobe.com

FDA Approves Cerliponase Alfa for Expanded Indication of CLN2 Disease

Ashley Gallagher, Associate Editor
July 24th 2024
Article
Pharmacy Focus: World Psychedelics Day

Pharmacy Focus: World Psychedelics Day

Ashley Gallagher, Associate Editor
June 14th 2024
Podcast
Coagulation Factor VIII, FVIII, an essential blood-clotting protein, also known as anti-hemophilic factor, AHF, 3D illustration

Intravenous Immunoglobulin Temporarily Improves Bleeding in Patients With Acquired Von Willebrand Syndrome

Luke Halpern, Assistant Editor
July 24th 2024
Article
Season 3 - Public Health Matters: A Look at Wearable Technology, AI-Assisted Innovations

Season 3 - Public Health Matters: A Look at Wearable Technology, AI-Assisted Innovations

January 25th 2024
Podcast
Study Shows Value of Investing in Pharmacogenomics Testing for Tacrolimus Dosing in Kidney Transplant Recipients

Study Shows Value of Investing in Pharmacogenomics Testing for Tacrolimus Dosing in Kidney Transplant Recipients

Alexander McCarthy, PharmD
July 19th 2024
Article
Drug-related adverse events, community pharmacy | Image Credit: sutlafk - stock.adobe.com

Better Prevention Strategies Rely on the Monitoring of Outpatient Adverse Drug Events

Ashley Gallagher, Associate Editor
July 17th 2024
Article